Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study

Yaerim Kim,Su-Kil Park,Won-Yong Cho,Kwon-Wook Joo,Sug Kyun Shin,Dae Joong Kim,Yong Lim Kim,Sung Hyun Son,Wookyung Chung,Kwang-Young Lee,Sung Kwang Park,Joong Kyung Kim,Soo Wan Kim,Duk-Hee Kang,Jin Kuk Kim,Jin Seok Jeon,Kang Wook Lee,Chang Hwa Lee,Dong-Jin Oh,Won Suk An,Jong Soo Lee,Gun Woo Kang,Jun Young Do,Jung Pyo Lee,Kyubok Jin

Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study

2019

Background Darbepoetin-alfa is an erythropoiesis-stimulating agent (ESA) with a long elimination half-life that achieves better hemoglobin (Hb) stability than short-acting ESAs.

Keywords:

Hemodialysis
double blinded
Darbepoetin alfa
Urology
Pharmacology
Biosimilar
Medicine
Hemoglobin
Pharmacotherapy
Randomization
Erythropoietin
Internal medicine
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations